CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

RapamycinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug1182 Glucose tablets Wiki 1.00
drug318 Azithromycin 500Mg Oral Tablet Wiki 1.00
drug1296 Hydroxychloroquine 200 Mg Oral Tablet Wiki 0.71
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D055370 Lung Injury NIH 0.20
D013577 Syndrome NIH 0.10
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.09
D012128 Respiratory Distress Syndrome, Adult NIH 0.08

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of Acute Respiratory Distress Syndrome (RAPA-CARDS)

This study assesses the clinical effectiveness of mammalian target of rapamycin (mTOR) inhibition with rapamycin in minimizing or decreasing the severity of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) in participants infected with mild to moderate COVID-19 virus.

NCT04482712 Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) Respiratory Failure Sars-CoV2 Drug: Rapamycin Drug: Placebo
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Respiratory Insufficiency Acute Lung Injury Lung Injury Syndrome

Primary Outcomes

Description: The proportion of participants who survive without respiratory failure

Measure: Survival rate

Time: 4 weeks

Secondary Outcomes

Description: The WHO ordinal scale is a measure of clinical improvement using a scale score of 0-8, where 0 indicates a better outcome and 8 indicates death: Uninfected, no clinical oor virological evidence of infection 0 Ambulatory, no limitation of activities 1 Ambulatory, limitation of activities 2 Hospitalized Mild disease, no oxygen therapy 3 Hospitalized mild disease, oxygen by mask or nasal prongs 4 Hospitalized Severe Disease, non-invasive ventilation 5 Hospitalized severe disease, intubation and mechanical ventilation 6 Hospitalized severe disease, ventilation+organ support 7 Death 8

Measure: Change in Clinical Status assessed by the World Health Organization (WHO) scale

Time: Baseline to 4 weeks

Description: An ordinal scale for clinical improvement scored from 1 to 8, where 1 represents death and 8 represents recovery to discharge from hospital with no limitation on activities: Death (1) Hospitalized, on invasive mechanical ventilation of extracorporeal membrane oxygenation (ECMO) (2) Hospitalized, on non-invasive ventilation or high flow oxygen devices (3) Hospitalized, requiring supplemental oxygen (4) Hospitalized, not requiring supplemental oxygen or ongoing medical care (6) Not hospitalized, limitation on activities &/or requiring supplemental home oxygen (7) Not hospitalized, no limitation on activities (8)

Measure: Change in Clinical Status assessed by the National Institute of Allergy and Infectious Disease (NIAID) scale

Time: Baseline to 4 weeks

Other Outcomes

Description: Total number of deaths during the study period

Measure: All cause mortality

Time: 4 weeks

Description: Number of days on ECMO

Measure: Duration of ECMO

Time: Up to 4 weeks

Description: Number of days participants are on supplemental oxygen

Measure: Duration of supplemental oxygen

Time: Up to 4 weeks

Description: Days of hospitalization

Measure: Length of hospital stay

Time: Up to 4 weeks

Description: Number of days until there is a negative response to the reverse transcriptase-polymerase chain reaction test (RT-PCR)

Measure: Length of time to SARS-CoV2 negativity

Time: Up to 4 weeks

No related HPO nodes (Using clinical trials)